SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Bozcuk H, Martin C. Does treatment delay affect survival in non-small cell lung cancer? A retrospective analysis from a single UK centre. Lung Cancer. 2001; 34: 243-252.
  • 2
    Eastham DV, Weerasuriya D, Wakelee H, et al. Quantification of progression of non-small cell lung cancer in the interval between diagnostic and radiotherapy treatment planning PET scans. Int J Radiat Oncol Biol Phys. 2007; 69( 3 suppl 1): S520-S521.
  • 3
    MacManus M, Bayne M, Everitt S, Ball D, Hicks R. High incidence of progression of non-small cell lung cancer between staging and treatment-planning FDG-PET/CT scans in candidates for radical radiation therapy [abstract]. Int J Radiat Oncol Biol Phys. 2006; 66( 3 suppl 1): S463. Abstract 2457.
  • 4
    O'Rourke N, Edwards R. Lung cancer treatment waiting times and tumour growth. Clin Oncol (R Coll Radiol). 2000; 12: 141-144.
  • 5
    Tann M, Sandrasegaran K, Winer-Muram HT, Jennings SG, Welling ME, Fletcher JW. Can FDG-PET be used to predict growth of stage I lung cancer? Clin Radiol. 2008; 63: 856-863.
  • 6
    Vinod S, Kaplan A. Growth of non-small cell lung cancer from diagnosis to radiotherapy treatment [abstract]. Lung Cancer. 2005; 49( suppl 2): S315. Abstract P-747.
  • 7
    Wang L, Correa CR, Hayman JA, et al. Time to treatment in patients with stage III non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2009; 74: 790-795.
  • 8
    Pieterman RM, van Putten JWG, Meuzelaar JJ, et al. Preoperative staging of non-small-cell lung cancer with positron-emission tomography. N Engl J Med. 2000; 343: 254-261.
  • 9
    Silvestri GA, Hoffman B, Reed CE. One from column A: choosing between CT, positron emission tomography, endoscopic ultrasound with fine-needle aspiration, transbronchial needle aspiration, thoracoscopy, mediastinoscopy, and mediastinotomy for staging lung cancer. Chest. 2003; 123: 333-335.
  • 10
    Chen Z, King W, Pearcey R, Kerba M, Mackillop WJ. The relationship between waiting time for radiotherapy and clinical outcomes: a systematic review of the literature. Radiother Oncol. 2008; 87: 3-16.
  • 11
    Friberg S, Mattson S. On the growth rates of human malignant tumors: implications for medical decision making. J Surg Oncol. 1997; 65: 284-297.
  • 12
    National Health and Medical Research Council. Clinical Practice Guidelines for the Prevention, Diagnosis and Management of Lung Cancer. Canberra, Australia: 2004.
  • 13
    Salomaa ER, Sallinen S, Hiekkanen H, Liippo K. Delays in the diagnosis and treatment of lung cancer. Chest. 2005; 128: 2282-2288.
  • 14
    MacManus M, Hicks RJ. The use of positron emission tomography (PET) in the staging/evaluation, treatment, and follow-up of patients with lung cancer: a critical review. Int J Radiat Oncol Biol Phys. 2008; 72: 1298-1306.
  • 15
    Toloza EM, Harpole L, McCrory DC. Noninvasive staging of non-small cell lung cancer: a review of the current evidence. Chest. 2003; 123( 1 suppl): 137S-146S.
  • 16
    Greene FL, Page, DL, Fleming ID. AJCC Cancer Staging Manual. 6th ed. New York, NY: Springer-Verlag; 2002.
  • 17
    Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest. 1997; 111: 1710-1717.
  • 18
    SobinLH, WittekindC, eds. TNM Classification of Malignant Tumors. 6th ed. New York, NY: John Wiley & Sons; 2002.
  • 19
    Nahmias C, Wahl LM. Reproducibility of standardized uptake value measurements determined by 18F-FDG PET in malignant tumors. J Nucl Med. 2008; 49: 1804-1808.
  • 20
    Bayne M, MacManus M, Hicks R, Leong T, Peters L, Ball D. Can a mathematical formula help define a radiation target volume using positron emission tomography? In regard to Black, et al. (Int J Radiat Oncol Biol Phys. 2004;60:1272-1282). Int J Radiat Oncol Biol Phys. 2005; 62: 299-300.
  • 21
    Jennings SG, Winer-Muram HT, Tann M, Ying J, Dowdeswell I. Distribution of stage I lung cancer growth rates determined with serial volumetric CT measurements. Radiology. 2006; 241: 554-563.
  • 22
    Norton L. A Gompertzian model of human breast cancer growth. Cancer Res. 1988; 48( 24 pt 1): 7067-7071.
  • 23
    Miller CW. Growth characteristics of pulmonary metastases from osteosarcoma. Clin Orthop Relat Res. 1976;( 116): 70-75.
  • 24
    Blomqvist C, Wiklund T, Tarkkanen M, Elomaa I, Virolainen M. Measurement of growth rate of lung metastases in 21 patients with bone or soft-tissue sarcoma. Br J Cancer. 1993; 68: 414-417.
  • 25
    Clavo AC, Brown RS, Wahl RL. Fluorodeoxyglucose uptake in human cancer cell lines is increased by hypoxia. J Nucl Med. 1995; 36: 1625-1632.
  • 26
    Ball D, Bryan B, Peter G, et al. Is tumor volume an independent prognostic factor in non-smallcell lung cancer (NSCLC) treated with radical radiotherapy? Interim analysis of the Trans-Tasman Radiation Oncology Group (TROG) database 99-05 [abstract]. Lung Cancer. 2005; 49( suppl 2): S208. Abstract P-351.
  • 27
    Joint Council for Clinical Oncology. Reducing Delays in Cancer Treatment: Some Targets. London, UK: Royal College of Physicians; 1993.
  • 28
    Mackillop WJ, Bates JH, O'Sullivan B, Withers HR. The effect of delay in treatment on local control by radiotherapy. Int J Radiat Oncol Biol Phys. 1996; 34: 243-250.